Coronavirus Notebook: UK OKs Second Bivalent Vaccine, European Companies Warn On Joint Vaccine Procurement Plans
Executive Summary
The Swiss medicines regulator has approved the bivalent version of Spikevax and given the green light to use of the Novavax COVID-19 vaccine in younger people.
You may also be interested in...
EU Regulator Eyes Mid-September For Decision On Comirnaty BA.4/BA.5 Booster Approval
As regulators continue to process and approve applications for new kinds of COVID-19 booster vaccines, evidence is still awaited on the real-world benefits conferred by the latest variant-adapted products. The European Medicines Agency and the European Centre for Disease Prevention and Control plan to issue a joint statement on the use of adapted vaccines next week, and the EMA has OKd a booster version of the Novavax vaccine.
EU OKs Bivalent COVID-19 Vaccines From Pfizer/BioNTech & Moderna
The European Commission will shortly issue marketing authorizations for bivalent versions of Comirnaty and Spikevax targeting the Omicron BA.1 subvariant, after the European Medicines Agency recommended their approval for EU-wide use. Bivalent Spikevax has also been provisionally approved in Australia.
UK First To Approve Moderna’s Bivalent COVID-19 Vaccine
The mRNA-1273.214 vaccine will add to the UK’s armory for protecting people against coronavirus over the coming winter season.